Skip to main content

Table 1 Volume market share and annual therapy cost per patient of new antidiabetic medicines, all insulins, and old antidiabetic medicines in 2016

From: Uptake of new antidiabetic medicines in 11 European countries

Country

Volume market share in 2016

Annual therapy cost in 2016

New antidiabetic medicinesa (%)

All insulins

(%)

Old antidiabetic medicines (%)

New antidiabetic medicinesa (€)

All insulins (€)

Old antidiabetic medicines (€)

Austria

26.1 (20.8)b

24.1

49.8

460

326

55.8

Croatia

10.8 (8.7)b

20.8

68.4

371

270

36.9

France

17.7 (14.6)b

21.1

61.3

480

386

56.6

Germany

22.9 (17.5)b

36.2

40.9

513

500

32.1

Hungary

10.3 (7.5)b

26.5

63.2

474

239

45.1

Italy

8.8 (6.3)b

21.5

69.7

499

326

43.3

Poland

1.5 (1.1)b

23.5

75.0

363

173

26.9

Slovenia

6.6 (4.1)b

29.0

63.5

427

284

58.0

Spain

26.3 (21.2)b

23.4

50.3

456

328

25.7

Sweden

9.7 (5.8)b

35.2

55.1

769

373

15.9

UK

10.6 (6.8)b

22.2

67.2

668

390

56.2

  1. Legend: aDPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
  2. bValues in brackets indicate the volume market share for DPP-4 inhibitors